Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:CASNumber |
2228327-56-6
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Allogene_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALLO-647
|
| gptkbp:intendedUse |
immunosuppression
|
| gptkbp:mechanismOfAction |
depletes NK cells
depletes T cells |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
CD52
|
| gptkbp:UNII |
6Q1K1Q1Q1Q
|
| gptkbp:usedIn |
allogeneic CAR T cell therapy
|
| gptkbp:bfsParent |
gptkb:Allogene_Therapeutics
|
| gptkbp:bfsLayer |
7
|